Genpharm ranitidine approved Aug. 22; Torpharm examining generic ranitidines for Form 1 patent infringement.
Executive Summary
GENPHARM RANITIDINE APPROVED AUG. 22, JOINING OTHER GENERIC MARKETERS receiving final ANDA approvals for the generic version of Glaxo Wellcome's Zantac. Glaxo's infringement suit against Genpharm was dismissed from the New York federal court Aug. 15, clearing a path for final approval. Boehringer Ingleheim and Geneva received approval Aug. 29; Novopharm has been marketing ranitidine since Aug. 1.